MedPath

FDA Approves Peytant Solutions' AMStent for Malignant Airway Obstructions

• Peytant Solutions received FDA de novo marketing authorization for its AMStent system, designed to treat tracheobronchial strictures caused by malignant neoplasms. • The AMStent system combines a minimally invasive catheter delivery system with a stent covered in amnion-derived material. • AMStent aims to improve airflow in the trachea or tracheobronchial tree, potentially reducing migration, inflammation, and mucus accumulation. • The approval offers a new palliative care option to improve the quality of life for patients with malignant airway obstructions.

Peytant Solutions has secured FDA marketing authorization for its AMStent tracheobronchial covered stent system, a novel therapy designed to alleviate pulmonary obstructions caused by cancer. The de novo nod allows the Plymouth, Minnesota-based company to market its AMStent system for treating tracheobronchial strictures produced by malignant neoplasms in adult patients.
The AMStent system represents Peytant's first product offering within its amnion-based covered stent platform. It uniquely combines a minimally invasive catheter delivery system with a stent covered in material derived from amnion. This design aims to address the challenges faced by cancer patients who develop malignant airway obstructions as their disease progresses.

Clinical Application and Benefits

Many patients with cancer experience malignant airway obstructions, necessitating palliative care to improve airflow in the trachea or tracheobronchial tree. The AMStent system facilitates this by dilating the lumen, allowing patients to receive routine airway stents. Peytant reports that the benefits of AMStent include reduced migration, decreased local inflammation and granuloma formation, and diminished mucus accumulation and occlusion.

Expert Commentary

Dr. Craig Walker, founder, president, and medical director of the Cardiovascular Institute of the South in Houma, Louisiana, hailed the system as "a unique option for patients who need it most." John Schorgl, Peytant co-founder and CEO, expressed optimism that the AMStent system will provide a much-needed option for patients suffering from tracheobronchial obstruction due to malignant tumors, with the goal of improving palliative care and quality of life.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Grants 510(k) Clearance to RELIEF Stent for Vesicoureteral Reflux

The FDA has approved the RELIEF ureteral stent for preventing vesicoureteral reflux, marking the first such approval in the U.S. The stent, developed by The Ureteral Stent Company, aims to address the significant side effects associated with current stents, such as reflux and bladder spasms, through its unique design.

FDA Approves Subcutaneous Opdivo Qvantig for Multiple Solid Tumors

The FDA approved Opdivo Qvantig, a subcutaneous injection of nivolumab, for adult solid tumors previously approved for intravenous Opdivo.
CheckMate-67T trial data showed non-inferior pharmacokinetic exposures, similar efficacy, and comparable safety to intravenous Opdivo.

Merit Medical's WRAPSODY Endoprosthesis Receives FDA Approval for Dialysis Patients

Merit Medical's WRAPSODY Cell-Impermeable Endoprosthesis receives FDA premarket approval, paving the way for its commercial launch in the U.S. in 2025.
The WRAPSODY device is designed to extend long-term vessel patency in dialysis patients by addressing stenosis and thrombosis in arteriovenous (AV) fistulas and grafts.

RevBio's Tetranite Bone Adhesive Trial Expanded Following FDA Nod, Gains CMS Reimbursement

RevBio received FDA approval to expand its clinical trial for Tetranite, a bone adhesive biomaterial, after demonstrating safety in initial patients.
The trial expansion allows Tetranite's use in intradural cases like tumor resection, beyond its initial extradural cranial flap fixation application.

Lungpacer's AeroPace System Receives FDA Approval for Ventilator Weaning

The FDA has granted premarket approval to Lungpacer Medical's AeroPace System, a neurostimulation therapy designed to improve weaning outcomes for adults on mechanical ventilation.
AeroPace stimulates the phrenic nerves to strengthen the diaphragm, leading to improved breathing and reduced dependence on mechanical ventilation for patients ventilated for at least 96 hours.

Antelope Surgical Solutions Receives FDA IND Approval for Radiofluorescent Prostate Cancer Drug AS1986NS

Antelope Surgical Solutions has received FDA approval for its Investigational New Drug (IND), AS1986NS, a radiofluorescent drug targeting prostate cancer.
AS1986NS combines therapeutic radioisotopes and imaging agents with a fluorescent linker to enhance surgical precision by illuminating cancer margins.

Antelope Surgical Solutions Receives FDA IND Approval for PSMA-Targeted Fluorescent Drug AS1986NS

Antelope Surgical Solutions has received FDA approval for its novel prostate cancer technology, AS1986NS, a radiofluorescent drug.
AS1986NS combines therapeutic radioisotopes with a fluorescent linker to enable targeted staining of prostate cancer cells during surgery.

FDA Approves First-of-its-Kind Stent for Infants with Pulmonary Stenosis and Aortic Coarctation

The FDA has approved a novel miniaturized cardiac stent (Minima, Renata Medical) for infants and small children with coarctation of the aorta or pulmonary artery stenosis.
In a pivotal trial, 97.6% of patients experienced effective relief from stenosis, with no additional surgical interventions required at 6 months.

FDA Approves Biotronik's Left Bundle Branch Area Pacing System

The FDA has granted approval for Biotronik's Selectra 3D catheter and Solia S lead system for left bundle branch area pacing (LBBAP).
The approval was based on the BIO-CONDUCT trial, which demonstrated a 95.7% implant success rate and a low 1.7% lead-related complication rate.

Restore Medical's ContraBand Device Receives FDA Breakthrough Designation for Heart Failure

Restore Medical's ContraBand system received FDA Breakthrough Device designation for treating heart failure with reduced ejection fraction (HFrEF).
The ContraBand device is a transcatheter pulmonary artery banding (PAB) system designed to improve the quality of life for HFrEF patients.

Reference News

[1]
Peytant wins FDA de novo nod for covered stent system - MassDevice
massdevice.com · Oct 22, 2024

Peytant Solutions receives FDA marketing authorization for its AMStent tracheobronchial covered stent system, designed t...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy